Aurobindo Pharma subsidiary Auro Peptides completed a comprehensive United States Food and Drug Administration inspection at its specialised manufacturing facility. The regulatory agency concluded the audit cycle with just a single operational observation regarding general facility maintenance, successfully averting major compliance disruptions for the pharmaceutical manufacturer.